Can-Fite BioPharma Ltd. (CANF)
AMEX: CANF
· Real-Time Price · USD
0.66
-0.01 (-1.79%)
At close: Aug 15, 2025, 3:59 PM
0.65
-1.62%
After-hours: Aug 15, 2025, 07:19 PM EDT
Can-Fite BioPharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 674K | 650K | 667K | 705K | 743K | 785K | 793K | 801K | 810K | 817K | 864K | 910K | 853K | 799K | 759K | 713K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 674K | 650K | 667K | 705K | 743K | 785K | 793K | 801K | 810K | 817K | 864K | 910K | 853K | 799K | 759K | 713K |
Operating Income | -8.13M | -7.95M | -7.79M | -7.53M | -8.2M | -9.44M | -10.15M | -10.44M | -10.1M | -11.04M | -11.98M | -13.04M | -12.84M | -12.37M | -11.34M | -12.03M |
Interest Income | n/a | 127K | 233K | 344K | 506K | 742K | 680K | 569K | 407K | 44K | 110K | 110K | 403K | 424K | 314K | 314K |
Pretax Income | -7.88M | -7.57M | -7.37M | -7.06M | -7.63M | -9M | -9.77M | -10.29M | -10.17M | -11.27M | -12.14M | -13.17M | -12.62M | -12.13M | -11.3M | -11.98M |
Net Income | -7.88M | -7.57M | -7.37M | -7.06M | -7.47M | -8.78M | -9.45M | -10.22M | -10.39M | -11.55M | -12.51M | -13.3M | -12.62M | -12.13M | -11.3M | -11.98M |
Selling & General & Admin | 3.05M | 3.01M | 3.01M | 2.87M | 2.96M | 3.06M | 3.04M | 3.24M | 3.14M | 3.45M | 3.53M | 3.58M | 3.85M | 3.52M | 3.39M | 3.26M |
Research & Development | 5.76M | 5.59M | 5.45M | 5.37M | 5.98M | 7.17M | 7.91M | 8M | 7.76M | 8.41M | 9.31M | 10.37M | 9.85M | 9.64M | 8.71M | 9.48M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 8.8M | 8.6M | 8.46M | 8.23M | 8.94M | 10.23M | 10.95M | 11.24M | 10.91M | 11.86M | 12.84M | 13.95M | 13.7M | 13.17M | 12.1M | 12.75M |
Interest Expense | n/a | 14K | 17K | 17K | 17K | 19K | 60K | 60K | 60K | 44K | 110K | 110K | 403K | 542K | 528K | 528K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 8.8M | 8.6M | 8.46M | 8.23M | 8.94M | 10.23M | 10.95M | 11.24M | 10.91M | 11.86M | 12.84M | 13.95M | 13.7M | 13.17M | 12.1M | 12.75M |
Income Tax Expense | n/a | n/a | -3.5K | -7.5K | -169.5K | -233.5K | -318K | -72K | 218K | 282K | 367K | 121K | -10K | -10K | -10.5K | -9.5K |
Shares Outstanding (Basic) | 8.44M | 8.44M | 6.07M | 6.07M | 4.95M | 4.08M | 4.09M | 3.93M | 2.72M | 2.72M | 2.72M | 2.72M | 1.36M | 1.83M | 1.72M | 1.61M |
Shares Outstanding (Diluted) | 8.44M | 8.44M | 6.07M | 6.07M | 4.95M | 4.08M | 4.08M | 3.93M | 2.72M | 2.72M | 2.72M | 2.72M | 2.22M | 1.83M | 1.72M | 1.61M |
EPS (Basic) | -1.14 | -1.23 | -1.41 | -1.5 | -1.83 | -2.61 | -3.12 | -3.51 | -3.75 | -5.67 | -6.6 | -7.65 | -7.92 | -7.23 | -7.05 | -8.97 |
EPS (Diluted) | -1.14 | -1.23 | -1.41 | -1.5 | -1.83 | -2.61 | -3.12 | -3.51 | -3.75 | -5.67 | -6.6 | -7.65 | -7.92 | -7.23 | -7.05 | -8.97 |
EBITDA | -8.12M | -7.94M | -7.78M | -7.52M | -8.18M | -9.43M | -10.14M | -10.42M | -10.08M | -11.03M | -11.96M | -13.03M | -12.83M | -12.35M | -11.32M | -12.02M |
EBIT | -8.13M | -7.95M | -7.79M | -7.53M | -8.2M | -9.44M | -10.15M | -10.44M | -10.1M | -11.04M | -11.98M | -13.04M | -12.84M | -12.31M | -11.28M | -11.97M |
Depreciation & Amortization | 7K | 7.75K | 8.25K | 11.75K | 14.75K | 14.5K | 14.5K | 13.5K | 13.5K | 13.5K | 13K | 14K | 13.5K | 13K | 13.5K | 12.5K |